BACKGROUND: Dexmedetomidine has been shown to blunt the stress response to surgery and anaesthesia. Hence our study was designed to evaluate the effect of intravenous (IV) Dexmedetomidine infusion on propofol & Sevoflurane requirements during general anesthesia for laparoscopic cholecystectomies without intra operative awareness. MATERIALS AND METHODS: 60 patients scheduled for laproscopic surgeries under general anesthesia were divided into Dexmedetomidine (D) group and Placebo (P) group of 30 each. Group D received a loading dose of Inj. Dexmedetomidine at 1 μg/kg diluted to 100 ml given over 15min, followed by maintenance with 0.5 μg/kg/h till the end of surgery. Group P received similar volume of IV normal saline (100 ml). Anesthesia was maintained with nitrous oxide in oxygen and Sevoflurane keeping BIS values between 40 to 60.Patients were monitored intraoperatively for haemodynamic variables, depth of anaesthesia propofol and sevoflurane consumption & postoperative pain. Results were analysed. RESULTS: 50% reduction (1 mg/kg) in the induction dose of propofol was observed along with a mean hourly Sevoflurane requirement of 15.54±2.8 in group D when compared to (2 mg/kg) propofol, 33.35±4.2 sevoflurane in group P to maintain adequate Depth of anaesthesia using BIS. In peri-operative period, the heart rate and blood pressures were significantly lower in Group D, when compared to placebo. Patients in Group D were better sedated and post-operative pain score was lower in Group D compared to Group P. CONCLUSION: Dexmedetomidine is an effective anesthetic adjuvant that reduces propofol & sevoflurane requirements without fear of intraoperative awareness.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.